Introdução: A enteroscopia por cápsula é o exame de primeira linha no diagnóstico de diversas patologias do intestino delgado. Este artigo tem por objectivo rever e analisar criticamente as indicações actuais para enteroscopia por cápsula na prática clínica. Material e Métodos: Revisão bibliográfica suportada em artigos indexados na PubMed. Resultados e Discussão: A enteroscopia por cápsula permite a avaliação não invasiva da mucosa do intestino delgado, com elevado rendimento diagnóstico. Em doentes com hemorragia digestiva de causa obscura, o rendimento da enteroscopia por cápsula aumenta quando realizada precocemente após o evento hemorrágico. O tratamento das angiectasias com enteroscopia assistida por balão permite diminuir a recidiva hemorrágica, enquanto o risco de recidiva em doentes com enteroscopia por cápsula "negativa" é controverso. A entero-TC/entero-RM podem superiorizar-se à enteroscopia por cápsula no diagnóstico de alguns tumores. O 'Smooth Protruding Index on Capsule Endoscopy' (score SPICE) auxilia na diferenciação entre verdadeiros tumores submucosos e abaulamentos não patológicos. A enteroscopia por cápsula é valiosa em doentes com suspeita de doença de Crohn quando a ileocolonoscopia não é diagnóstica, permitindo também estadiar a extensão e actividade das lesões em doentes com diagnóstico prévio de doença de Crohn, com potenciais implicações prognósticas e terapêuticas. A enteroscopia por cápsula permite ainda o diagnóstico de complicações em doentes com doença celíaca refractária. Conclusões: Actualmente, a importância da enteroscopia por cápsula é reconhecida no contexto da hemorragia digestiva de causa obscura e/ou suspeita de tumores do intestino delgado, bem como na suspeita de doença de Crohn ou em doentes com doença de Crohn conhecida para determinar a localização, extensão e actividade da doença, e ainda para a investigação de doentes com doença celíaca refractária. Palavras-chave: Doenças Intestinais; Endoscopia por Cápsula.
INTRODUCTION
Small bowel capsule endoscopy (SBCE) has assumed a central role in the investigation of many diseases affecting the small bowel. It enables a non-invasive evaluation of the entire lenght of the small bowel, providing the highest diagnostic yield among all of currently available noninvasive diagnostic modalities. 1 The European Society of Gastrointestinal Endoscopy (ESGE) has recently endorsed a comprehensive guide for the clinical application of enteroscopy. 2 The main indications for SBCE are obscure gastrointestinal bleeding (OGIB) and suspected or known Crohn's disease (CD), followed by other less frequent clinical indications such as suspected small bowel tumors, surveillance of polyposis syndromes and coeliac disease.
MATERIAL AND METHODS
This review article was based on a critical analysis of the most relevant and/or recent papers indexed in the PubMed regarding clinical applications of SBCE.
RESULTS AND DISCUSSION Obscure gastrointestinal bleeding
Obscure gastrointestinal bleeding (OGIB) is defined as bleeding from the gastrointestinal tract that remains undiagnosed after esophagogastroduodenoscopy (EGD) and colonoscopy, generally corresponding to midgastrointestinal bleeding, i.e., the origin of bleeding being located in the small bowel between the ampulla of Vater and the ileocecal valve. 3 Clinically, OGIB may present in the form of occult (positive fecal occult blood test and/or irondeficiency anemia) or overt bleeding (passage of visible blood, usually as melena or hematochezia). It accounts for approximately 5% of all gastrointestinal haemorrhage and up to 30% of all cases of iron-deficiency anemia, 4 although in up to 25% of the cases, the origin of bleeding may in fact be related to missed or recently healed lesions within the reach of EGD or colonoscopy. A systematic review including over 20.000 patients reported OGIB as the most common indication for SBCE, accounting for almost two thirds of cases. 5 In that large review, the most common lesions responsible for bleeding were angioectasias ( Fig. 1) , accounting for approximately half of the cases, 5 while ulcers and inflammatory lesions, often related to nonsteroidal anti-inflammatory drugs (NSAIDs) or Crohn's disease, accounted for 26.8% of cases, 8.8% of patients had small bowel neoplastic lesions and 7.7% had other less common type of lesions responsible for the OGIB.
Diagnostic yield of SBCE
In a meta-analysis by Triester et al, 1 the diagnostic yield of SBCE was superior to push enteroscopy [incremental yield (IY) = 30%], small bowel follow-through (IY = 36%), CT enteroclysis (IY = 38%) and MRI (IY = 36%) in patients with OGIB. Marmo et al 6 reported an absolute pooled difference in the rate of positive findings of SBCE versus alternative modalities of 41% (95% CI: 35.6% -45.9%). The diagnostic yield of SBCE is similar to double-balloon (DBE) providing that both oral and anal insertion route are performed. 7 In routine clinical practice, SBCE is usually the initial test because of its non-invasiveness, ability to view the entire small bowel, and guidance of the initial route of balloon-assisted enteroscopy (BAE), in those cases where patients with positive findings on SBCE will require biopsies or therapeutic intervention. 8 Koulaouzidis et al 9 reported a pooled diagnostic yield of 66.6% (95% CI: 61.0% -72.3%) in patients with iron-deficiency anemia submitted to SBCE.
Acute overt OGIB
In patients with overt bleeding, the diagnostic yield of SBCE is higher if performed early after its onset. Pennazio et al 10 reported a significantly higher diagnostic yield in patients with ongoing overt OGIB (92.3%) versus occult OGIB (44.2%) or previous history of overt OGIB (12.9%).
Bresci et al
11 reported a diagnostic yield of 92% when SBCE was performed within the first two weeks after the diagnosis of OGIB, versus 34% when it was performed later than the second week. Lecleire et al 12 followed a cohort of patients with severe overt OGIB, with negative upper and lower endoscopies performed within 72h after admission, and urgent SBCE performed within the subsequent 48h. Fresh blood was seen in 75% and relevant lesions were detected in 67% of patients, leading to further endoscopic (54%), surgical (22%), or radiological (2%) procedures. In another recent study of 144 patients with overt OGIB, SBCE resulted in higher detection rate of active bleeding and/or angioectasias (44.4% vs 27.8%, p = 0.046) when performed within 72h of hospital admission. 13 In a randomized controlled trial, Leung et al 14 found that the diagnostic yield of SBCE was higher than angiography (53.3% vs 20%; p = 0.016) in patients with severe overt OGIB, and the cumulative risk of rebleeding was 16.7% and 33.3%, respectively (p = 0.10). The use of BAE as the first line examination in this setting has been advocated as a cost-effective approach, due to the high probability of positive findings and the possibility of immediate therapeutic intervention. 15 However, SBCE may still prove useful in those cases, by indicating the optimal route of insertion and by diagnosing possible synchronous lesions.
Rebleeding
Patients with multiple small bowel angioectasias seem to be at the highest risk of bleeding during the follow-up after SBCE. 16 Some authors reported a significant decrease in the risk of rebleeding after SBCE-guided therapeutic interventions. 17 In a recent prospective multicenter study, 18 the rate of rebleeding at twelve months among patients with small bowel vascular lesions detected by SBCE and 20 described that a 'negative' SBCE predicts low rebleeding rates (11% versus 42%, p < 0.05). Interestingly, in this study none of the patients with 'occult' OGIB and 'negative' SBCE experienced rebleeding. However, other authors have reported higher rates of up to 25% of patients with OGIB and negative SBCE experiencing rebleeding, 21, 22 the vast majority within the first two years of follow-up. The overall miss rate for SBCE has been estimated at 10% -30%, and solitary lesions are more likely to be missed. 23 These different outcomes may reflect distinct inclusion criteria, baseline clinical characteristics or duration of follow-up, as well as differences in inclusion criteria, particularly the case of P1 lesions, such as small erosions or red spots, which have uncertain bleeding potential according to the classification of Saurin et al, 24 while P2 lesions (angioectasias, ulcers, tumors or varices) have a well recognized bleeding risk. Imagawa et al demonstrated improved visibility and detectability 25 of small bowel lesions when using flexible spectral imaging color enhancement (FICE); hence, it could be a reasonable approach to review all 'negative' SBCE using the FICE mode before proceeding to further diagnostic investigations.
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Small bowel tumors and polyposis syndromes
The most common clinical presentation of small bowel tumors is obscure GI bleeding (OGIB). 27 The prevalence of small bowel tumors in patients with OGIB has been reported to range between 5% and 10%, 28,29 malignant tumors accounting for 60% to 75% of cases. 27 In a large multicenter study, 29 the main primary small bowel tumor type was gastrointestinal stromal tumor (GIST) (32%), followed by adenocarcinoma (20%) and carcinoid tumor (15%) (Fig. 2) ; two thirds of metastatic tumors in the small bowel corresponded to melanomas. Up to 70% of the tumors detected by SBCE have been missed by previous imaging studies, particularly when smaller than 10 mm. 28 However, SBCE also has limitations and even large, protruding masses can be overlooked or seen only tangentially on one limited frame of the video. 30 Moreover, SBCE is often unable to distinguish benign from malignant tumors, or even neoplastic from non-neoplastic lesions 31 . In a pooled analysis of 24 prospective studies (n = 530 patients), the failure rate of SBCE in detecting small bowel tumors was reported at 18.9%.
32 SBCE can miss single mass lesions because of limited field of vision, poor bowel preparation, rapid transit especially in the proximal small bowel (duodenum and proximal jejunum), folds and loop angulations hiding masses, lack of insufflation, noncontinuous image capture or incomplete examination. 30 Thus, patients should be further investigated after a nondiagnostic SBCE if there is a high suspicion of small bowel tumor. Cross-sectional imaging techniques such as CT or MR enterography allow for the detection of hypervascular small bowel masses, enable extraluminal assessment and identify possible metastatic lesions for staging purposes. Nonetheless, in clinical practice, the tumor is often diagnosed by SBCE in the first place, in patients being investigated for OGIB; subsequently, patients will often undergo crosssectional imaging for staging and eventually proceed to BAE to obtain biopsies for histopathologic diagnosis; BAE may also be used to remove retained capsules proximal to the tumor, as the risk of capsule retention has been reported to be high in this population, ranging from 1.4% to 17%. 27 From a practical point of view, if there is a suspicion of small bowel tumor based on previous cross-sectional imaging studies, BAE could be preferred over SBCE, in order to avoid the risk of capsule retention and to allow biopsies for histopathologic diagnosis. The diagnostic yield of DBE has been shown to be similar to the combination of CTE and SBCE, 33 and the specificity is higher, mainly due to the high rate of false positive submucosal masses detected by SBCE. 34 
Differentiating a submucosal tumoral lesion from an innocent bulge on SBCE
Up to half of small bowel malignancies found by SBCE correspond to GIST or neuroendocrine tumors, endoscopically appearing as smooth, round, protruding lesions. 29, 35 Those lesions may be difficult to distinguish from 'innocent' bulges that result from bowel angulation or the impression of an adjacent loop, particularly if some features suggestive of tumoral lesions are absent, such as bleeding, ulceration or irregular surface. 31 The prevalence of smooth, round protrusions at SBCE has been estimated Rosa 35 The Smooth Protruding Index on Capsule Endoscopy (SPICE score) 35 may be helpful to discriminate a bulge from a true mass on SBCE.
Polyposis syndromes
The recently released guidelines of the American College of Gastroenterology (ACG) have thoroughly reviewed on the genetic testing and management of hereditary gastrointestinal cancer syndromes.
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Peutz-Jeghers syndrome (PJS) is characterized by the development of benign hamartomatous polyps in the gastrointestinal tract, especially the small bowel, in association with muco-cutaneous pigmentation. Large (> 10 -15 mm) small bowel polyps are prone to complications such as acute gastrointestinal bleeding, intussusception or bowel obstruction, and also have a malignant potential. 37 Small bowel surveillance allows for the detection of large polyps and further referral for endoscopic or surgical removal. The recent ACG guidelines suggest to start with SBCE at age 8 years; if polyps are present, repeat every 3 years; if no polyps are detected, SBCE should be repeated at age 18, then every 3 years, or earlier if symptoms occur. 36 However, it is recognized that even large polyps may be missed by SBCE, especially if located in the proximal small bowel. Gupta et al 38 followed a cohort of 19 patients with 41 polyps greater than 10 mm, which were detected by either MRE or SBCE. Although SBCE was better for the identification of smaller polyps (6 -10mm), it missed three large polyps (> 15 mm) that were detected by MRE. Thus, these examinations may be considered complementary. In patients with familial adenomatous polyposis (FAP), there is no evidence to support the routine use of SBCE when the diagnosis is established, 31, 36 as standard endoscopy is superior for the detection of periampullary and duodenal polyps. 39 There is also no current indication for the routine use of SBCE in patients with a diagnosis of Lynch syndrome. 31, 36 In a recent study of 200 asymptomatic patients with Lynch syndrome, 40 the prevalence of small bowel neoplasia was 1.5%, and all neoplastic lesions were located in the duodenum, easily accessible to conventional EGD. The risk of capsule retention may be increased in some patients with polyposis syndromes, such as FAP patients with intra-abdominal desmoid tumors or patients with PJS who underwent previous small bowel surgical resections; therefore, small bowel cross-sectional imaging and/or patency capsule should be performed if SBCE is being considered.
Crohn's disease
Suspected Crohn's disease. Ileocolonoscopy remains the first line examination in patients with suspected Crohn's disease (CD). However, SBCE may be considered, in the absence of obstructive symptoms or known stenosis, when ileocolonoscopy is non-diagnostic, when retrograde ileoscopy is not technically feasible, or when small bowel lesions proximal to the level reached by the colonoscope are suspected. 41 In patients with suspected small bowel stenoses, SBCE should only be considered if functional patency of the small bowel is previously confirmed by small bowel cross-sectional imaging and/or the Agile™ patency capsule. 42 SBCE has a high sensitivity for lesions consistent with small bowel CD, including mild lesions and those located in the proximal small bowel. [43] [44] [45] In patients with suspected CD, it is possible to confidently exclude the diagnosis when no lesions are identified by SBCE 46 . However, the lesions which are typical of active small bowel CD, such as villous oedema or aphthous ulcerations (Fig. 3) , are not diseasespecific, looking similar to other entities such as NSAIDs enteropathy, tuberculosis, Behçet's disease, ulcerative jejuno-ileitis, lymphoma, small bowel ischemia or radiation enteropathy. 41 There are no validated diagnostic criteria for establishing the diagnosis of CD by SBCE. The Lewis Score (LS) and the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) have been validated as cumulative quantitative scores that measure the severity of inflammatory activity, and contribute to standardise reporting and increase interobserver agreement. 47, 48 A software application for the automatic calculation of the LS is available in the Rapid Reader ® workstation (Given Imaging, Yokneam, Israel). However, although these scoring systems can quantitatively describe the type, distribution and severity of mucosal lesions, they cannot be used independently as a diagnostic tool, as they grade inflammatory activity regardless of its etiology. Hence, careful patient selection remains essential to increase the specificity and the positive predictive value of SBCE findings. Direct assessment and biopsies may be important in patients in whom diagnoses such as infections or malignancy, which may mimic the clinical presentation of CD, have to be excluded. 49 The In patients with known CD, irrespective of the findings at ileocolonoscopy, the small bowel should be investigated to evaluate disease extent and activity, 52 as it may influence prognosis and therapeutic decisions. Cross sectional imaging with CTE or MRE generally takes precedence over SBCE, being able to identify strictures and to assess the transmural and extra-luminal nature of the disease and its anatomical distribution. In the absence of clinical or radiological evidence of stenoses, SBCE may be considered if additional findings are likely to result in a modification of clinical management. 53 Although the risk of capsule retention is slightly increased in these patients, it can often be managed conservatively or retrieved by BAE. 54 SBCE improves the detection of lesions in the proximal small bowel when compared to both CTE and MRE, detecting proximal lesions in up to 50% of patients with previously diagnosed ileal CD. 55 Jejunal involvement has been recognized as an independent marker of severity in CD, being associated with an increased risk of relapse, 55 higher use of corticosteroids (HR 1.24; 95% CI: 1.02 -1.50) and thiopurines (HR 1.26; 95% CI: 1.06 -1.49), higher rates of strictureplasties (RR 2.52; 95% CI: 1.60 -3.96), hospitalizations (RR 1.29; 95% CI: 1.14 -1.47), and longer hospitalization duration (RR, 1.30; 95% CI, 1.25 -1.34). 56 Recently, it was reported that treatment with thiopurines and/or biologics was started more often in patients with proximal small bowel lesions detected by SBCE [13/33 (39%) vs 1/17 (6%), p = 0.011, relative risk (RR) 6.5], particularly when severe (6%, 36% and 45% of patients with non-significant, mild and moderate-to-severe inflammation, respectively).
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Patients with suspected obscure GI bleeding or ongoing symptoms.
SBCE has been used to investigate CD patients in the setting of unexplained iron-deficiency anemia or visible OGIB, 41 or to investigate patients with ongoing symptoms suggestive of active disease. 57 Mehdizadeh et al 58 reported normal SBCE findings in 48% of symptomatic patients with small bowel CD, guiding the investigation to alternative diagnoses such as concurrent irritable bowel syndrome, bile salt malabsorption or bacterial overgrowth.
Assessment of mucosal healing
Small bowel mucosal healing is an important endpoint of treatment efficacy. The use of validated quantitative scales with good inter-observer agreement such as the Lewis score 59 or the CECDAI, 47 with adoption of a standardized definition of mucosal healing, seems particularly relevant in this setting. SBCE enables a longitudinal assessment of the course of the disease and its response to medical therapy. 60, 61 However, there is currently insufficient evidence to support its use for this indication in routine clinical practice.
Postoperative disease recurrence
Pons Beltran et al 62 evaluated 24 CD patients for postoperative recurrence. SBCE detected CD neo-terminal ileal disease recurrence in 62% of patients, whereas ileocolonoscopy detected inflammatory lesions within the neo-terminal ileum in 25% of patients. Conversely, in another study, the sensitivity of SBCE for endoscopic recurrence in the neo-terminal ileum was inferior to that of ileocolonoscopy, although proximal lesions were detected in more than two thirds of patients. 63 Although SBCE has been shown to detect proximal small bowel lesions in patients with CD early after surgery, the clinical significance of these findings and how they may impact on patient management is currently unknown. Thus, SBCE should currently be considered only when ileocolonoscopy is unsuccessful for the assessment of postoperative recurrence.
Celiac disease
Celiac disease is one of the most prevalent enteropathies in western countries, affecting 0.2 -2% of the population. 64 The first step for diagnosing celiac disease is usually a serological test, using the immunoglobulin A (IgA) antihuman tissue transglutaminase (t-TG) and IgA endomysial antibody immunofluorescence (EMA). Although serological testing is highly sensitive and specific, EGD with biopsies of the duodenum remains the standard for the diagnosis of celiac disease. Four typical endoscopic markers of celiac disease have been described: loss or reduction in duodenal Kerkring's folds, mosaic or micronodular mucosal pattern, scalloped configuration of duodenal folds and visibility of the underlying blood vessels. 65 The reported specificity for these classical endoscopic markers ranges from 87% to 100%, while the sensitivity may range from 50% to 94%. 65, 66 Therefore, small bowel histopathology remains essential for the diagnosis, typically showing villous atrophy, increased intraepithelial lymphocytes and hyperplastic crypts. 65 However, adequate and properly oriented tissue samples are sometimes difficult to obtain, and patchy mucosal lesions may be missed, precluding a definite histopathologic diagnosis. A few studies have reported a sensitivity of 67% -93%, specificity of 63.6% -100%, positive predictive value (PPV) of 96.5% -100% and negative predictive value (NPV) of 60% -89% for the diagnosis of celiac disease with SBCE. 67, 68 Barret et al 69 reported that the concordance of SBCE with histology for villous atrophy was better than that of upper GI endoscopy (kappa coefficient = 0.45 vs 0.24, p < 0.001). In a meta-analysis, El-Matary et al 70 reported a pooled sensitivity and specificity of SBCE for the diagnosis of celiac disease of 83% (95% CI: 71% -90%) and 98% (95% CI: 88% -99.6%), respectively, while another recent meta-analysis 71 reported a pooled sensitivity of 89% (95% CI: 82% -94%) and specificity of 95% (95% CI: 89 -98%). In view of these results, it remains a topic of discussion whether SBCE could be a valid diagnostic examination in selected cases, such as in patients unable or unwilling to undergo conventional upper GI endoscopy, or those with positive serologic tests and negative duodenal biopsies. In patients with an established diagnosis of celiac disease, SBCE has the main advantage of being a non-invasive technique capable of visualizing the entire small bowel, establishing the extent of small bowel involvement and enabling the diagnosis of complications of long-standing celiac disease, such as small bowel adenocarcinoma, enteropathy associated T-cell lymphoma (EATL) and ulcerative jejuno-ileitis, which are often located beyond the site reached by EGD, and may also be missed by other small bowel imaging modalities. Petroniene et al 65 reported that the extent of small bowel involvement may be related to the severity of symptoms in celiac disease. Poor nutritional status and low serum albumin levels have also been associated with extensive small bowel damage. 72 Extensive ulcerative jejuno-ileitis may be observed in more than half of patients with refractory celiac disease (RCD) type II (54%) and it is associated with a high risk of developing EATL. 69 The risk of capsule retention in patients with suspected complications of longstanding celiac disease advices preliminary radiological imaging of the small bowel or patency capsule in order to rule out stricturing disease. 42, 69 In a series of 47 high risk celiac patients with persistent unexplained abdominal pain, weight loss, history of small bowel neoplasia, long-standing celiac disease, positive faecal occult blood test or iron deficiency anaemia unresponsive to iron supplementation, SBCE detected significant lesions in approximately 60% of cases. 73 These data support the use of SBCE in patients with long-standing complicated celiac disease, who present with alarm symptoms or do not respond to gluten-free diet.
CONCLUSIONS
SBCE revolutionized the diagnostic approach of small bowel diseases, and its relative positioning within the management algorithms of patients with OGIB, suspected small bowel tumors, CD and coeliac disease has been rapidly evolving in the past few years. In the future, new features such as the ability to obtain new image reconstructions, sample luminal fluids and mucosal tissue or the possibility to remotely control the capsule and performing therapeutic procedures are likely to further expand the field of capsule technology,
